|Videos|October 28, 2022
An Overview of Advanced Basal Cell Carcinoma (BCC) and Currently Available Treatment Options
Dr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.
Episodes in this series
Related to this article
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The resubmission of the BLA for RP1 has been accepted for review by the FDA for use in combination with nivolumab in advanced melanoma.
Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving biomarker utilization and sequencing strategies in uveal melanoma.
The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
3
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
4
Taking Science from Bench to Bedside to the Block – Introducing Dr. Robert A. Winn
5